Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (21-30 of 491) with videos related to

Pageof 50
Sort By:
The Lancet. Oncology|February 3, 2009
Emergency surgery in the era of molecular treatment of solid tumoursPiotr Rutkowski, Włodzimierz Ruka
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 24, 2022
New roads in retroperitoneal sarcomasPiotr Rutkowski, Sylvie Bonvalot
Expert Opinion on Drug Safety|April 16, 2020
An update on the safety of nivolumab for the treatment of advanced melanomaAnna M Czarnecka, Piotr Rutkowski
Annals of Translational Medicine|April 21, 2023
Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastasesPiotr Rutkowski, Anna M Czarnecka
Frontiers in Oncology|June 26, 2020
Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of PatientsMateusz Jacek Spałek, Piotr Rutkowski
Annals of Surgical Oncology|February 10, 2023
Perioperative Therapy in Melanoma: Several Questions Still RemainPiotr Rutkowski, Hanna Koseła-Paterczyk
Expert Review of Anticancer Therapy|October 10, 2017
Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomasHanna Koseła-Paterczyk, Piotr Rutkowski
Translational Cancer Research|July 21, 2025
How to treat systemic recurrences following adjuvant immunotherapyPiotr Rutkowski, Hanna Koseła-Paterczyk
Expert Opinion on Biological Therapy|May 18, 2023
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanomaHanna Koseła-Paterczyk, Piotr Rutkowski
Expert Opinion on Biological Therapy|November 8, 2023
What role can LAG-3-blocking antibodies play in melanoma therapy?Piotr Rutkowski, Paulina Jagodzińska-Mucha
Pageof 50

Showing results (21-30 of 491) with videos related to

Sort By:
Pageof 50
The Lancet. Oncology|February 3, 2009
Emergency surgery in the era of molecular treatment of solid tumoursPiotr Rutkowski, Włodzimierz Ruka
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 24, 2022
New roads in retroperitoneal sarcomasPiotr Rutkowski, Sylvie Bonvalot
Expert Opinion on Drug Safety|April 16, 2020
An update on the safety of nivolumab for the treatment of advanced melanomaAnna M Czarnecka, Piotr Rutkowski
Annals of Translational Medicine|April 21, 2023
Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastasesPiotr Rutkowski, Anna M Czarnecka
Frontiers in Oncology|June 26, 2020
Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of PatientsMateusz Jacek Spałek, Piotr Rutkowski
Annals of Surgical Oncology|February 10, 2023
Perioperative Therapy in Melanoma: Several Questions Still RemainPiotr Rutkowski, Hanna Koseła-Paterczyk
Expert Review of Anticancer Therapy|October 10, 2017
Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomasHanna Koseła-Paterczyk, Piotr Rutkowski
Translational Cancer Research|July 21, 2025
How to treat systemic recurrences following adjuvant immunotherapyPiotr Rutkowski, Hanna Koseła-Paterczyk
Expert Opinion on Biological Therapy|May 18, 2023
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanomaHanna Koseła-Paterczyk, Piotr Rutkowski
Expert Opinion on Biological Therapy|November 8, 2023
What role can LAG-3-blocking antibodies play in melanoma therapy?Piotr Rutkowski, Paulina Jagodzińska-Mucha
Pageof 50